And so, one other working week will quickly draw to an in depth. Not a second too quickly, sure? That is, you could recall, our treasured sign to daydream about weekend plans. Our agenda, for essentially the most half, is quite modest. We plan to atone for our studying, promenade with the official mascots, hang around at a porchfest, and maintain nonetheless one other listening social gathering, the place the rotation will doubtless embrace this, this, this, this and this. And what about you? It is a superb time to benefit from the nice open air. You may stroll alongside the shore or get pleasure from metropolis streets. These of you with additional power may manicure the grounds or eliminate the piles of undesirable objects stuffed across the premises. You may calm down with a pleasant ebook or plan a summer time getaway. So many selections, sure? Effectively, no matter you do, have a grand time. However be secure. Get pleasure from, and see you quickly. …
Lars Fruergaard Jørgensen, who led Novo Nordisk because it rode the increase of its weight problems and diabetes medicines to develop into one of many greatest gamers within the pharmaceutical business, solely to see that success stall in latest months, is stepping down as chief govt officer, STAT notes. Jørgensen, who has labored at Novo for greater than 30 years and has led the corporate for the previous eight years, will proceed within the place for a interval “to help a clean transition to new management,” the corporate stated in a press release. The seek for the subsequent chief govt officer is below manner. In explaining the transfer, Novo famous that gross sales, earnings, and share value have nearly tripled throughout Jørgensen’s tenure, because it turned the frontrunner within the race to market GLP-1 diabetes and weight problems therapies. However the firm acknowledged that the manager changeup is being “made in mild of the latest market challenges Novo Nordisk has been going through,” particularly citing the collapse of its share value over the previous yr, a stretch when it has fallen by half.
The Trump administration desires to carry the manufacturing of extra medication, together with medicines like antibiotics that could be briefly provide, nearer to the affected person — together with contained in the hospital, Bloomberg Information says. The partnership between among the nation’s high well being businesses and a handful of corporations, together with the Mark Cuban Price Plus Drug Firm, is meant to make use of synthetic intelligence and different instruments to make eight medication within the locations the place individuals really get medical care. The therapies embrace generic medication akin to levetiracetam, which treats epilepsy, the native anesthetic lidocaine, the chemotherapy carboplatin, albuterol sulfate for bronchial asthma, and the antibiotic linezolid. Hospitals have the capability to provide therapies on the level of care, often via a course of known as compounding, when commercially out there medication will not be appropriate. If profitable, the brand new program, known as Equip-A-Pharma, would bolster the U.S. drug manufacturing system and doubtlessly mitigate drug shortages.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
